Gilead Sciences is a research-based biopharmaceutical
company that discovers, develops and commercializes medicines. Their primary
focus areas include HIV/AIDS, hepatitis B and C, cardiovascular and respiratory
conditions. They are a global company with operations in North America, Europe
and Asia Pacific. They have many
products as shown below in this table.
Cayston
|
Lexiscan/Rapiscan
|
Complera/Eviplera
|
Emtriva
|
Tamiflu
|
AmBisome
|
Viread
|
Hepsera
|
Vistide
|
Truvada
|
Letairis
|
|
Macugen
|
Atripla
|
Ranexa
|
In addition to their amazing number of products, they
also acquired this past January the company Pharmasset, Inc. Pharmasset is a
clinical-stage pharmaceutical company that focuses on developing and
commercializing novel drugs to treat viral infections. This will complements
Gilead’s pipeline drugs that relates to hepatitis and HIV/AIDs.
A very positive and up and coming company. It has many different
drugs in phase I, II, and III trials. For the treatment of liver alone, it has
9 different drugs. Many of them are NS5B nucleoside and/or nucleotide inhibitors.
In addition to a 1 monoclonal antibody for treatment of liver fibrosis, several
protease inhibitors for treatment of hepatitis C
The stock is very close to
its 52 week’s high. The S& P 500 has upgraded Gilead to 5 stars! Thomson
Reuters has it dab in the middle at 5, and Second Opinion Weekly Report
upgraded its rating of Gilead 91 days ago to Long and Improving. When you look
at the 3 month chart of Gilead, you can see that the technicals (MACD) are
going positive. I agree with these rating systems. Gilead is a strong company
with many cards in the air, so that it is going to do good in the long run. I
would not be surprised if it continued to increase in value.
(Information is from Scottrade and Gilead.com)
No comments:
Post a Comment